Published research, by compound

Retatrutide for obesity — Phase 2 trial

The New England journal of medicine·2023Human clinical study

Retatrutide in obesity pharmacotherapy

Biomolecules·2025Peer-reviewed study

Retatrutide in obesity and diabetes therapy

European journal of pharmacology·2024Peer-reviewed study

Retatrutide for type 2 diabetes — Phase 2 trial

Lancet (London, England)·2023Human clinical study

Retatrutide for fatty liver disease — Phase 2a trial

Nature medicine·2024Human clinical study

Retatrutide for obesity — systematic review & meta-analysis

Proceedings (Baylor University. Medical Center)·2025Systematic review of trials

Retatrutide on weight & metabolic markers — meta-analysis

Metabolism open·2024Systematic review of trials

Retatrutide — TRIUMPH clinical trial program

Diabetes, obesity & metabolism·2026Human clinical study

Retatrutide and body composition in type 2 diabetes — Phase 2

The lancet. Diabetes & endocrinology·2025Human clinical study

Retatrutide for obesity — review of clinical trials

Journal of basic and clinical physiology and pharmacology·2025Systematic review of trials

Intranasal NAP (davunetide) decreases tau hyperphosphorylation and improves behavioral deficits

Pharmacology Research & Perspectives·2014Animal study

NAP (davunetide) provides functional and structural neuroprotection

Current Pharmaceutical Design·2011Peer-reviewed review

Davunetide (AL-108) on cognition and functional capacity in schizophrenia

Schizophrenia Research·2012Human clinical trial

BPC-157 peptide: medical applications — literature & patent review

Pharmaceuticals (Basel, Switzerland)·2025Peer-reviewed study

BPC-157 and musculoskeletal soft-tissue healing

Cell and tissue research·2019Peer-reviewed study

BPC-157 in orthopaedic sports medicine — systematic review

HSS journal : the musculoskeletal journal of Hospital for Special Surgery·2025Systematic review

BPC-157 and wound healing

Frontiers in pharmacology·2021Peer-reviewed study

BPC-157 and knee pain — clinical study

Alternative therapies in health and medicine·2021Peer-reviewed study

BPC-157, growth factors & tissue healing

Current pharmaceutical design·2018Peer-reviewed study

BPC-157 and the central nervous system

Neural regeneration research·2022Peer-reviewed study

BPC-157 and NSAID-induced gut damage

Current pharmaceutical design·2020Peer-reviewed study

BPC-157 for musculoskeletal healing — narrative review

Current reviews in musculoskeletal medicine·2025Peer-reviewed review

BPC-157 and tendon-cell healing — lab study

Journal of applied physiology (Bethesda, Md. : 1985)·2011Lab / formulation study

GHK-Cu tripeptide in liposomes — cosmetic study

Pharmaceutics·2023Lab / formulation study

GHK-Cu microsphere filler — anti-inflammatory study

Colloids and surfaces. B, Biointerfaces·2025Lab / formulation study

GHK-Cu skin permeation in liposomes

Molecules (Basel, Switzerland)·2025Lab / formulation study

GHK-Cu and lung inflammation / fibrosis

Redox biology·2024Peer-reviewed study

GHK-Cu and ACL healing — rat model

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2015Animal-model study

GHK-Cu, oxidative stress & aging

Oxidative medicine and cellular longevity·2012Peer-reviewed study

GHK copper-peptide complex — chemistry study

International journal of molecular sciences·2020Peer-reviewed study

GHK-Cu and pulmonary fibrosis — animal model

Life sciences·2020Animal-model study

Copper-tripeptide hydrogel and wound healing

Biomaterials research·2025Lab / formulation study

Recombinant GHK tripeptide and copper toxicity — zebrafish

Biomolecules·2020Lab / formulation study

Tesamorelin — overview

·2012Peer-reviewed study

Tesamorelin in HIV patients — clinical study

AIDS (London, England)·2024Peer-reviewed study

Tesamorelin — drug profile

Nature reviews. Drug discovery·2011Peer-reviewed study

Tesamorelin — research update

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation·2010Peer-reviewed review

Tesamorelin and HIV-associated lipodystrophy — review

Drugs·2011Peer-reviewed review

Tesamorelin growth-hormone analogue — HIV lipodystrophy

The Annals of pharmacotherapy·2012Peer-reviewed study

Tesamorelin — growth-hormone-releasing analogue

Expert opinion on investigational drugs·2009Peer-reviewed study

Tesamorelin and fatty liver in HIV (NAFLD)

JCI insight·2020Peer-reviewed study

GHK as an anti-aging peptide

Aging pathobiology and therapeutics·2020Peer-reviewed study

GHK peptide and skin-regeneration pathways

BioMed research international·2015Mechanistic study

GHK-Cu skin permeation in liposomes

Molecules (Basel, Switzerland)·2025Lab / formulation study

GHK copper-peptide complex — chemistry study

International journal of molecular sciences·2020Peer-reviewed study

Copper-peptide delivery through skin — microneedle study

Pharmaceutical research·2015Lab / formulation study

Copper-free GHK and skin stem cells

Journal of peptide science : an official publication of the European Peptide Society·2012Lab / formulation study

GHK tripeptide and tissue remodeling

Journal of biomaterials science. Polymer edition·2008Peer-reviewed study

GHK-Cu tripeptide in liposomes — cosmetic study

Pharmaceutics·2023Lab / formulation study

GHK-Cu, oxidative stress & aging

Oxidative medicine and cellular longevity·2012Peer-reviewed study

Copper-tripeptide hydrogel and wound healing

Biomaterials research·2025Lab / formulation study

BPC-157 and musculoskeletal soft-tissue healing

Cell and tissue research·2019Peer-reviewed study

BPC-157 and wound healing

Frontiers in pharmacology·2021Peer-reviewed study

BPC-157 in tissue repair & pain research

International journal of molecular sciences·2026Peer-reviewed study

BPC-157, growth factors & tissue healing

Current pharmaceutical design·2018Peer-reviewed study

BPC-157 and tendon-cell healing — lab study

Journal of applied physiology (Bethesda, Md. : 1985)·2011Lab / formulation study

Injectable peptides in regenerative medicine — review

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association·2025Peer-reviewed study

Therapeutic peptides in orthopaedics — review

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2026Peer-reviewed review

Injectable peptide therapy — orthopaedic primer

The American journal of sports medicine·2026Peer-reviewed study

BPC-157 and blood vessels

Current pharmaceutical design·2014Peer-reviewed study

BPC-157 and healing

Journal of physiology, Paris·1997Peer-reviewed study

Ipamorelin and chemotherapy weight loss — animal study

Physiology & behavior·2024Animal-model study

Ipamorelin — first selective GH secretagogue

European journal of endocrinology·1998Peer-reviewed study

Therapeutic peptides in orthopaedics — review

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2026Peer-reviewed review

Ipamorelin and bone growth — rats

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·1999Animal-model study

Ipamorelin pharmacokinetics in human volunteers

Pharmaceutical research·1999Human clinical study

Ipamorelin pharmacokinetics & nasal absorption

Xenobiotica; the fate of foreign compounds in biological systems·1998Peer-reviewed study

GH secretagogue hybrids of ipamorelin — chemistry

Bioorganic & medicinal chemistry letters·2001Peer-reviewed study

GH secretagogues and body composition — review

Translational andrology and urology·2020Peer-reviewed study

Ipamorelin and somatotroph response — rats

Histology and histopathology·2002Animal-model study

Ipamorelin and steroid-related bone loss — rats

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2001Animal-model study

KPV tripeptide and inflammatory bowel disease — animal model

Inflammatory bowel diseases·2008Animal-model study

KPV hydrogel and oral mucositis

Biomaterials science·2021Animal-model study

Anti-inflammatory effects of α-MSH-related peptides

Advances in experimental medicine and biology·2010Peer-reviewed study

KPV tripeptide and intestinal inflammation

Gastroenterology·2008Peer-reviewed study

KPV nanoparticle delivery and ulcerative colitis

Molecular therapy : the journal of the American Society of Gene Therapy·2017Lab / formulation study

Colon-targeted nanoparticle delivery and colitis — mouse model

Gastroenterology·2010Animal-model study

KPV-stabilizing hydrogel and ulcerative colitis — rats

ACS biomaterials science & engineering·2021Animal-model study

PepT1 and KPV tripeptide in colitis-associated cancer — mouse

Cellular and molecular gastroenterology and hepatology·2016Animal-model study

Structural modification of the KPV tripeptide

PloS one·2018Peer-reviewed study

α-MSH tripeptide and corneal wound healing

Experimental eye research·2006Peer-reviewed study

Beta-thymosins — overview

Annals of the New York Academy of Sciences·2007Peer-reviewed study

Thymosin beta-4 in regenerative therapy research

International immunopharmacology·2023Peer-reviewed study

Thymosin beta-4 and the eye

Expert opinion on biological therapy·2018Peer-reviewed study

Thymosin beta-4 and tissue repair in heart injury

Current medicinal chemistry·2020Peer-reviewed study

Thymosin beta-4 and liver (hepatic stellate) cells

Vitamins and hormones·2016Lab / formulation study

Thymosin beta-4 tissue-repair peptide — animal studies

Annals of the New York Academy of Sciences·2010Peer-reviewed study

Thymosin beta-4 and bacterial keratitis

International immunopharmacology·2023Animal-model study

Thymosin beta-4 and kidney (glomerular) disease

Kidney international·2016Animal-model study

Thymosin beta-4 in glioblastoma research

Brain : a journal of neurology·2014Peer-reviewed study

Thymosin beta-4 and middle-ear healing

International immunopharmacology·2023Animal-model study

MOTS-c and metabolic disorders

Metabolites·2023Mechanistic study

MOTS-c and muscle-atrophy signaling

American journal of physiology. Endocrinology and metabolism·2021Mechanistic study

MOTS-c mitochondrial peptide — therapeutic overview

Frontiers in endocrinology·2023Mechanistic study

MOTS-c as a mitochondrial regulator of the nucleus

BioEssays : news and reviews in molecular, cellular and developmental biology·2019Mechanistic study

MOTS-c, metabolism & insulin resistance

Cell metabolism·2015Mechanistic study

MOTS-c and ovarian cancer — mechanism study

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024Mechanistic study

MOTS-c and pulmonary fibrosis

Mitochondrion·2023Peer-reviewed study

MOTS-c and gestational diabetes

Pharmacological research·2022Mechanistic study

MOTS-c and bone metabolism

Frontiers in physiology·2023Mechanistic study

MOTS-c in aging and age-related disease

International journal of molecular sciences·2022Human clinical study

NAD+ in aging biology — review

Endocrine reviews·2023Peer-reviewed review

NAD+ and skin aging — pharmacological study

Cells·2024Lab / formulation study

NAD+ and sirtuins in aging

Trends in cell biology·2014Peer-reviewed study

NAD+ in aging, metabolism & neurodegeneration

Science (New York, N.Y.)·2015Mechanistic study

NMN safety & anti-aging — human clinical trials

Advances in nutrition (Bethesda, Md.)·2023Human clinical study

NAD+ decline and CAR-T cell function

Nature cancer·2025Lab / formulation study

NAD+ metabolism in cellular ageing

Nature reviews. Molecular cell biology·2021Mechanistic study

NMN as an anti-aging product — promises & safety

Journal of advanced research·2022Peer-reviewed study

NAD+ metabolism, senescence & aging

Aging cell·2024Mechanistic study

NAD+ signaling in neurological disorders

Antioxidants & redox signaling·2023Mechanistic study

Melanotan II — melanogenesis & skin pigmentation (phase I)

Life Sciences·1996Human clinical study

Melanotan II and thermogenesis — mouse model

Experimental physiology·2021Animal-model study

Melanotan II and feeding behavior — brain study

Neuropeptides·2022Peer-reviewed study

Melanotan II and diet-induced memory impairment

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023Animal-model study

Melanotan II and cisplatin ototoxicity

Hearing research·2002Peer-reviewed study

Melanotan II melanocortin agonist — human studies

International journal of impotence research·2000Peer-reviewed study

Melanotan II and nerve regeneration — rat

European journal of pharmacology·2003Animal-model study

Melanotan II and renal infarction — case review

CEN case reports·2020Peer-reviewed review

Melanotan II — qualitative forum study

Dermatology (Basel, Switzerland)·2021Peer-reviewed study

Use of melanotan I and II — population study

BMJ (Clinical research ed.)·2009Peer-reviewed study

Melanotan II and insulin sensitivity — rat model

Peptides·2004Animal-model study

Afamelanotide — overview

·2012Peer-reviewed study

Melanocortin system and metabolic disorders

Nature reviews. Endocrinology·2023Mechanistic study

Afamelanotide in skin disease — review

Postepy dermatologii i alergologii·2024Peer-reviewed review

Acne pathogenesis and anti-acne agents

Archives of dermatological research·2019Peer-reviewed study

Afamelanotide and phototoxicity in protoporphyria

Expert review of clinical pharmacology·2021Peer-reviewed study

Afamelanotide in protoporphyria — review

American journal of clinical dermatology·2016Peer-reviewed review

Afamelanotide — dermatology applications review

Journal of drugs in dermatology : JDD·2021Peer-reviewed review

Afamelanotide for protoporphyria — NEJM

The New England journal of medicine·2015Peer-reviewed study

Afamelanotide pharmacokinetics & clinical use

Clinical pharmacokinetics·2017Human clinical study

Afamelanotide and dermal phototoxicity

Expert review of clinical pharmacology·2015Peer-reviewed study

IGF-1 LR3 and amyloid plaques — mouse model

Journal of Alzheimer's disease : JAD·2025Animal-model study

IGF-1 LR3 and protein metabolism — cattle

Domestic animal endocrinology·1999Animal-model study

Recombinant IGF-1 LR3 expression — lab study

Applied microbiology and biotechnology·2023Lab / formulation study

IGF-1 LR3 and growth markers — pigs

The Journal of endocrinology·1997Animal-model study

IGF-1 LR3 muteins — protein design study

Growth factors (Chur, Switzerland)·1996Peer-reviewed study

IGF-1 LR3 and intestinal absorption

Growth factors (Chur, Switzerland)·2002Peer-reviewed study

IGF-1 LR3 and organ growth — guinea pig

The Journal of endocrinology·1995Animal-model study

IGF-1 and bone-marrow cell development — mouse

Endocrine·1998Animal-model study

IGF binding protein-3 and prostate cancer — mechanism

Oncogene·2007Mechanistic study

IGF and IGF-binding proteins — ovarian cells

Endocrinology·1992Lab / formulation study

Kisspeptin-10 and bone loss — mechanism study

Nature communications·2024Peer-reviewed study

Kisspeptin, energy balance & reproduction

Nature reviews. Endocrinology·2020Mechanistic study

Kisspeptin-10 and heart collagen — mechanism study

Scientific reports·2023Peer-reviewed study

Pubertal development and regulation — review

The lancet. Diabetes & endocrinology·2016Mechanistic study

Kisspeptin-10 in pregnancy — dairy cows

Veterinaria italiana·2022Animal-model study

Kisspeptin-10 and sperm preservation — buffalo

Andrologia·2022Animal-model study

Kisspeptin-10 and neuron toxicity — in vitro

International journal of molecular sciences·2022Animal-model study

Kisspeptin-10 and progesterone — bovine cells

Genes·2022Animal-model study

Kisspeptin antagonists — overview

Advances in experimental medicine and biology·2013Peer-reviewed study

Kisspeptin-10 and neuronal mitochondria — lab study

International journal of molecular sciences·2023Lab / formulation study